Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2022-08-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
南微医学科技股份有限公司独立董事关于公司第三届董事会第八次会议相关事项的独立意见
Regulatory Filings
2022-08-18 Chinese
南微医学科技股份有限公司2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年半年度报告' which translates to '2022 Half-Year Report'. It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and operational details for the period January 1 to June 30, 2022. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. It is not merely an announcement or a certification, but a full report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2022
2022-08-18 Chinese
南微医学科技股份有限公司持股5%以上股东减持计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement by a company disclosing a plan by a major shareholder (holding more than 5% of shares) to reduce their shareholding. It details the shareholder's identity, shareholding percentages, reduction plan specifics, timing, and risk disclosures. There is no financial data, earnings, or management discussion. The content matches the definition of a Major Shareholding Notification, which involves notifying changes or planned changes in significant share ownership levels. The document is not a report, earnings release, or regulatory filing but a specific announcement about shareholding changes.
2022-08-12 Chinese
南微医学科技股份有限公司持股5%以上股东减持计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's current holdings, the planned reduction amount, methods, timing, and reasons. The document is titled as a '持股5%以上股东减持股份计划公告' which translates to 'Announcement of Shareholding Reduction Plan by Shareholders Holding More Than 5%'. This fits the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels. The document is not a full financial report, earnings release, or regulatory filing, but a specific announcement about shareholding changes by a major shareholder. The document length is 2268 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is MRQ with high confidence.
2022-07-29 Chinese
南微医学科技股份有限公司首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the listing and circulation of previously restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period expiration, shareholder commitments, and related approvals. The document does not contain financial statements or detailed financial performance data but rather focuses on share circulation and compliance with regulatory requirements. The length is about 3,214 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a formal disclosure about share circulation and compliance, not a financial report or earnings release.
2022-07-15 Chinese
南京证券股份有限公司关于南微医学科技股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings
2022-07-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.